OBJECTIVES: To investigate the association of single nucleotide polymorphisms (SNPs) with nevirapine concentrations following intra-partum single-dose nevirapine. METHODS: Plasma and DNA samples were obtained from 330 HIV-infected Thai women who received intra-partum single-dosenevirapine in the PHPT-2 clinical trial to prevent perinatal HIV transmission. Nine SNPs within CYP2B6, CYP3A4 and ABCB1 were genotyped by real-time PCR. Nevirapine plasma concentrations were determined by HPLC and used in a population pharmacokinetic analysis. RESULTS: Higher nevirapine exposure was observed in women carrying the CYP2B6 516G>T polymorphism, but this did not reach statistical significance (P = 0.054). The TGATC CYP2B6 haplotype (g.3003T, 516G, 785A, g.18492T and g.21563C) was associated with increased nevirapine clearance and lower exposure (P = 0.0029). The median time for nevirapine concentrations to reach 10 ng/mL post-partum (nevirapine IC(50) for HIV-1) was 14 days [interquartile range (IQR, 14-18)] for TGATC homozygotes, 16 days (14-20) for TGATC heterozygotes and 18 days (14-20) for non-TGATC homozygotes (P = 0.020). CONCLUSIONS: The CYP2B6 516G>T impact on nevirapine concentrations was less pronounced after intra-partum single-dose nevirapine than reported under steady-state conditions, perhaps due to lack of enzyme auto-induction at the time of dosing. Although the TGATC CYP2B6 haplotype may shorten the persistence of nevirapine post-partum, its practical implications for the prevention of HIV transmission or selection of resistance mutations are likely limited.
RCT Entities:
OBJECTIVES: To investigate the association of single nucleotide polymorphisms (SNPs) with nevirapine concentrations following intra-partum single-dose nevirapine. METHODS: Plasma and DNA samples were obtained from 330 HIV-infected Thai women who received intra-partum single-dose nevirapine in the PHPT-2 clinical trial to prevent perinatal HIV transmission. Nine SNPs within CYP2B6, CYP3A4 and ABCB1 were genotyped by real-time PCR. Nevirapine plasma concentrations were determined by HPLC and used in a population pharmacokinetic analysis. RESULTS: Higher nevirapine exposure was observed in women carrying the CYP2B6 516G>T polymorphism, but this did not reach statistical significance (P = 0.054). The TGATC CYP2B6 haplotype (g.3003T, 516G, 785A, g.18492T and g.21563C) was associated with increased nevirapine clearance and lower exposure (P = 0.0029). The median time for nevirapine concentrations to reach 10 ng/mL post-partum (nevirapine IC(50) for HIV-1) was 14 days [interquartile range (IQR, 14-18)] for TGATC homozygotes, 16 days (14-20) for TGATC heterozygotes and 18 days (14-20) for non-TGATC homozygotes (P = 0.020). CONCLUSIONS: The CYP2B6 516G>T impact on nevirapine concentrations was less pronounced after intra-partum single-dose nevirapine than reported under steady-state conditions, perhaps due to lack of enzyme auto-induction at the time of dosing. Although the TGATC CYP2B6 haplotype may shorten the persistence of nevirapine post-partum, its practical implications for the prevention of HIV transmission or selection of resistance mutations are likely limited.
Authors: Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191
Authors: Christoph Wyen; Heidy Hendra; Martin Vogel; Christian Hoffmann; Heribert Knechten; Norbert H Brockmeyer; Johannes R Bogner; Jürgen Rockstroh; Stefan Esser; Hans Jaeger; Thomas Harrer; Stefan Mauss; Jan van Lunzen; Nicole Skoetz; Alexander Jetter; Christiane Groneuer; Gerd Fätkenheuer; Saye H Khoo; Deirdre Egan; David J Back; Andrew Owen Journal: J Antimicrob Chemother Date: 2008-02-14 Impact factor: 5.790
Authors: Akihiko Saitoh; Elizabeth Sarles; Edmund Capparelli; Francesca Aweeka; Andrea Kovacs; Sandra K Burchett; Andrew Wiznia; Sharon Nachman; Terence Fenton; Stephen A Spector Journal: AIDS Date: 2007-10-18 Impact factor: 4.177
Authors: Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Sara Gibbons; Mauro Sciandra; Daniela Colucci; Stefano Bonora; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen Journal: Clin Infect Dis Date: 2008-11-01 Impact factor: 9.079
Authors: Kevin C Brown; Mina C Hosseinipour; Janelle M Hoskins; Ranjit K Thirumaran; Hsiao-Chuan Tien; Ralf Weigel; Jean Tauzie; Ida Shumba; Jatinder K Lamba; Erin G Schuetz; Howard L McLeod; Angela D M Kashuba; Amanda H Corbett Journal: Pharmacogenomics Date: 2011-11-23 Impact factor: 2.533
Authors: C Sukasem; W Manosuthi; N Koomdee; S Santon; T Jantararoungtong; S Prommas; M Chamnanphol; A Puangpetch; S Sungkanuparph Journal: Infection Date: 2013-11-30 Impact factor: 3.553
Authors: Saran Vardhanabhuti; Edward P Acosta; Heather J Ribaudo; Patrice Severe; Umesh Lalloo; Nagalingeshwaran Kumarasamy; Frank Taulo; Joseph Kabanda; Olola Oneko; Prudence Ive; Pradeep Sambarey; Ellen S Chan; Jane Hitti; Francis Hong; Deborah McMahon; David W Haas Journal: J Infect Dis Date: 2013-05-17 Impact factor: 5.226
Authors: Julie Bertrand; Monidarin Chou; Danielle M Richardson; Céline Verstuyft; Paul D Leger; France Mentré; Anne-Marie Taburet; David W Haas Journal: Pharmacogenet Genomics Date: 2012-12 Impact factor: 2.089